School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa; Department of Health Sciences, Faculty of Health and Applied Sciences, Namibia University of Science and Technology, Windhoek, Namibia.
Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg, South Africa; Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy.
AIDS Rev. 2020 Oct 26;23(1):1-12. doi: 10.24875/AIDSRev.20000039.
We performed a systematic review and meta-analysis to investigate the impact of antiretroviral therapy (ART) on immune activation and reconstitution in people living with human immunodeficiency virus (PLWH). The PubMed electronic database and gray literature were searched from inception until March 2020. Studies were included if they reported the levels of immune activation and reconstitution at baseline and post-treatment. The random-effect model was used to calculate effect sizes. We included a total of ten studies comprising of 1 553 PLWH with an average age of 38.02 ± 10.10 years and a male/female ratio of 3.76. Pooled estimates showed a modest increase in the level of immune activation post-treatment (SMD: 0.64 [95% CI: -1.34, 2.63]; I2 = 98%, pH < 0.00001). In addition, treatment with ART significantly reconstituted the immune system (SMD: 0.70 [95% CI: 0.27, 1.44]; I2 = 68%, pH = 0.009). Notably, the level of immune reconstitution was independent of viral load or the treatment duration but dependent on the class of ARV drugs. Consequently, protease inhibitors were associated with the highest degree of immune restoration, followed by chemokine antagonists and lastly integrase inhibitors. In conclusion, immune activation persists in PLWH despite viral suppression and the degree of immune reconstitution is dependent on the drug class. Therefore, inclusion of protease inhibitors in ART may be of great benefit in immune restoration in patients with very low CD4 count.
我们进行了一项系统评价和荟萃分析,以调查抗逆转录病毒疗法(ART)对人类免疫缺陷病毒(PLWH)感染者免疫激活和重建的影响。从创建到 2020 年 3 月,我们在 PubMed 电子数据库和灰色文献中进行了搜索。如果研究报告了基线和治疗后免疫激活和重建的水平,则将其纳入研究。我们使用随机效应模型计算效应大小。我们共纳入了 10 项研究,共纳入了 1553 名平均年龄为 38.02±10.10 岁的 PLWH,男女比例为 3.76。汇总估计显示,治疗后免疫激活水平略有增加(SMD:0.64 [95%CI:-1.34,2.63];I2 = 98%,pH < 0.00001)。此外,ART 治疗可显著重建免疫系统(SMD:0.70 [95%CI:0.27,1.44];I2 = 68%,pH = 0.009)。值得注意的是,免疫重建的程度与病毒载量或治疗持续时间无关,但与 ARV 药物的类别有关。因此,蛋白酶抑制剂与最高程度的免疫恢复相关,其次是趋化因子拮抗剂,最后是整合酶抑制剂。总之,尽管病毒得到抑制,但 PLWH 仍存在免疫激活,免疫重建的程度取决于药物类别。因此,在 ART 中包含蛋白酶抑制剂可能对 CD4 计数非常低的患者的免疫恢复有很大益处。